QQQ   379.12 (+0.31%)
AAPL   149.32 (+0.46%)
MSFT   310.11 (+0.64%)
FB   315.81 (-3.92%)
GOOGL   2,786.17 (+1.35%)
TSLA   1,018.43 (-0.63%)
AMZN   3,376.07 (+1.68%)
NVDA   247.17 (+6.70%)
BABA   169.99 (-3.51%)
NIO   40.47 (-1.94%)
CGC   13.17 (-2.95%)
GE   107.44 (+2.03%)
AMD   122.93 (+0.47%)
MU   68.94 (+0.26%)
T   25.37 (-1.05%)
F   15.94 (-0.38%)
ACB   7.03 (-2.09%)
DIS   172.04 (+0.02%)
PFE   43.56 (+0.95%)
BA   209.81 (-1.44%)
AMC   36.05 (-2.12%)
QQQ   379.12 (+0.31%)
AAPL   149.32 (+0.46%)
MSFT   310.11 (+0.64%)
FB   315.81 (-3.92%)
GOOGL   2,786.17 (+1.35%)
TSLA   1,018.43 (-0.63%)
AMZN   3,376.07 (+1.68%)
NVDA   247.17 (+6.70%)
BABA   169.99 (-3.51%)
NIO   40.47 (-1.94%)
CGC   13.17 (-2.95%)
GE   107.44 (+2.03%)
AMD   122.93 (+0.47%)
MU   68.94 (+0.26%)
T   25.37 (-1.05%)
F   15.94 (-0.38%)
ACB   7.03 (-2.09%)
DIS   172.04 (+0.02%)
PFE   43.56 (+0.95%)
BA   209.81 (-1.44%)
AMC   36.05 (-2.12%)
QQQ   379.12 (+0.31%)
AAPL   149.32 (+0.46%)
MSFT   310.11 (+0.64%)
FB   315.81 (-3.92%)
GOOGL   2,786.17 (+1.35%)
TSLA   1,018.43 (-0.63%)
AMZN   3,376.07 (+1.68%)
NVDA   247.17 (+6.70%)
BABA   169.99 (-3.51%)
NIO   40.47 (-1.94%)
CGC   13.17 (-2.95%)
GE   107.44 (+2.03%)
AMD   122.93 (+0.47%)
MU   68.94 (+0.26%)
T   25.37 (-1.05%)
F   15.94 (-0.38%)
ACB   7.03 (-2.09%)
DIS   172.04 (+0.02%)
PFE   43.56 (+0.95%)
BA   209.81 (-1.44%)
AMC   36.05 (-2.12%)
QQQ   379.12 (+0.31%)
AAPL   149.32 (+0.46%)
MSFT   310.11 (+0.64%)
FB   315.81 (-3.92%)
GOOGL   2,786.17 (+1.35%)
TSLA   1,018.43 (-0.63%)
AMZN   3,376.07 (+1.68%)
NVDA   247.17 (+6.70%)
BABA   169.99 (-3.51%)
NIO   40.47 (-1.94%)
CGC   13.17 (-2.95%)
GE   107.44 (+2.03%)
AMD   122.93 (+0.47%)
MU   68.94 (+0.26%)
T   25.37 (-1.05%)
F   15.94 (-0.38%)
ACB   7.03 (-2.09%)
DIS   172.04 (+0.02%)
PFE   43.56 (+0.95%)
BA   209.81 (-1.44%)
AMC   36.05 (-2.12%)
NASDAQ:VBIV

VBI Vaccines Stock Forecast, Price & News

$2.95
-0.07 (-2.32 %)
(As of 10/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.93
$3.08
50-Day Range
$2.80
$3.72
52-Week Range
$2.07
$4.83
Volume2.26 million shs
Average Volume4.03 million shs
Market Capitalization$755.22 million
P/E RatioN/A
Dividend YieldN/A
Beta2.04
30 days | 90 days | 365 days | Advanced Chart
Receive VBIV News and Ratings via Email

Sign-up to receive the latest news and ratings for VBI Vaccines and its competitors with MarketBeat's FREE daily newsletter.


VBI Vaccines logo

About VBI Vaccines

VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of infectious disease and immuno-oncology vaccines. The firm focuses on the prevention and treatment of hepatitis B through its product pipeline, the Sci-B-Vac and VBI-2601. It also develops enveloped virus-like particle (eVLP) platform technology, which allows the development of eVLP vaccines that closely mimic the target virus to elicit a potent immune response. The company was founded on April 9, 1965 and is headquartered in Cambridge, MA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VBIV
Employees
130
Year Founded
N/A

Sales & Book Value

Annual Sales
$1.06 million
Book Value
$0.70 per share

Profitability

Net Income
$-46.23 million
Net Margins
-7,014.58%

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$755.22 million
Next Earnings Date
11/1/2021 (Estimated)
Optionable
Optionable

MarketRank

Overall MarketRank

1.99 out of 5 stars

Medical Sector

589th out of 1,363 stocks

Pharmaceutical Preparations Industry

280th out of 667 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -












VBI Vaccines (NASDAQ:VBIV) Frequently Asked Questions

Is VBI Vaccines a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for VBI Vaccines in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VBI Vaccines stock.
View analyst ratings for VBI Vaccines
or view top-rated stocks.

What stocks does MarketBeat like better than VBI Vaccines?

Wall Street analysts have given VBI Vaccines a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but VBI Vaccines wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is VBI Vaccines' next earnings date?

VBI Vaccines is scheduled to release its next quarterly earnings announcement on Monday, November 1st 2021.
View our earnings forecast for VBI Vaccines
.

How were VBI Vaccines' earnings last quarter?

VBI Vaccines Inc. (NASDAQ:VBIV) released its quarterly earnings data on Sunday, August, 1st. The biopharmaceutical company reported ($0.07) EPS for the quarter, meeting the consensus estimate of ($0.07). The biopharmaceutical company had revenue of $0.14 million for the quarter, compared to the consensus estimate of $0.55 million. VBI Vaccines had a negative trailing twelve-month return on equity of 37.04% and a negative net margin of 7,014.58%.
View VBI Vaccines' earnings history
.

How has VBI Vaccines' stock been impacted by COVID-19 (Coronavirus)?

VBI Vaccines' stock was trading at $0.9171 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, VBIV shares have increased by 221.7% and is now trading at $2.95.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for VBIV?

2 Wall Street analysts have issued 1-year price targets for VBI Vaccines' shares. Their forecasts range from $7.00 to $7.00. On average, they anticipate VBI Vaccines' stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 137.3% from the stock's current price.
View analysts' price targets for VBI Vaccines
or view top-rated stocks among Wall Street analysts.

Who are VBI Vaccines' key executives?

VBI Vaccines' management team includes the following people:
  • Jeff Baxter, President, Chief Executive Officer & Director
  • Christopher McNulty, CFO, Director & Head-Business Development
  • Francisco Diaz-Mitoma, Chief Medical Officer
  • David Evander Anderson, Chief Scientific Officer
  • T. Adam Buckley, Vice President-Business Development

What other stocks do shareholders of VBI Vaccines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other VBI Vaccines investors own include Canaccord Genuity (), BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities (), Sterne Agee CRT (), Robert W. Baird () and Wellington Shields ().

What is VBI Vaccines' stock symbol?

VBI Vaccines trades on the NASDAQ under the ticker symbol "VBIV."

Who are VBI Vaccines' major shareholders?

VBI Vaccines' stock is owned by many different institutional and retail investors. Top institutional shareholders include FNY Investment Advisers LLC (0.01%). Company insiders that own VBI Vaccines stock include Life Sciences Maste Perceptive and Perceptive Advisors Llc.
View institutional ownership trends for VBI Vaccines
.

Which institutional investors are selling VBI Vaccines stock?

VBIV stock was sold by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC. Company insiders that have sold VBI Vaccines company stock in the last year include Life Sciences Maste Perceptive, and Perceptive Advisors Llc.
View insider buying and selling activity for VBI Vaccines
or view top insider-selling stocks.

How do I buy shares of VBI Vaccines?

Shares of VBIV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is VBI Vaccines' stock price today?

One share of VBIV stock can currently be purchased for approximately $2.95.

How much money does VBI Vaccines make?

VBI Vaccines has a market capitalization of $755.22 million and generates $1.06 million in revenue each year. The biopharmaceutical company earns $-46.23 million in net income (profit) each year or ($0.21) on an earnings per share basis.

How many employees does VBI Vaccines have?

VBI Vaccines employs 130 workers across the globe.

What is VBI Vaccines' official website?

The official website for VBI Vaccines is www.vbivaccines.com.

Where are VBI Vaccines' headquarters?

VBI Vaccines is headquartered at 222 Third Street Suite 2241, Cambridge MA, 02142.

How can I contact VBI Vaccines?

VBI Vaccines' mailing address is 222 Third Street Suite 2241, Cambridge MA, 02142. The biopharmaceutical company can be reached via phone at (617) 830-3031 or via email at [email protected].


This page was last updated on 10/26/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.